psoriasis
Novartis’ Cosentyx approved in China for plaque psoriasis
April 2, 2019Manufacturing and Production, Sales and Marketing China, Cosentyx, Novartis, pharma, psoriasis
Novartis has revealed that its interleukin-17A (IL-17A) Cosentyx (secukinumab) has been authorised for use in China in the treatment of …
Japan awards AbbVie’s Skyrizi with first approval, in 4 psoriasis indications
March 27, 2019Research and Development, Sales and Marketing AbbVie, Japan, Skyrizi, pharma, psoriasis
AbbVie has announced that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has been awarded approval in Japan from the nation’s Ministry …
Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial
March 5, 2019Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis
New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …
AbbVie’s Skyrizi scoops up CHMP recommendation for moderate to severe plaque psoriasis
March 4, 2019Sales and Marketing AbbVie, pharma, psoriasis
AbbVie’s interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab) has secured recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP), …
NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis
December 4, 2018Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis
UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …
Janssen’s Tremfya maintains skin clearance after 3 years in plaque psoriasis
October 22, 2018Research and Development, Sales and Marketing Janssen, Tremfya, pharma, plaque psoriasis, psoriasis
Janssen has revealed new long-term data for its IL-23 inhibitor Tremfya (guselkumab) in moderate to severe plaque psoriasis, demonstrating skin …
Celgene’s Otezla impresses at Phase 3 in scalp psoriasis
October 9, 2018Manufacturing and Production, Research and Development Celgene, pharma, psoriasis
Celgene has unveiled new Phase 3 data for Otezla (apremilast), its inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine …
Almirall’s Ilumetri scores EU approval in chronic plaque psoriasis
September 19, 2018Research and Development, Sales and Marketing Almirall, EADV 2018, Ilumetri, pharma, psoriasis
Hot on the heels of the European Academy of Dermatology and Venereology Congress (EADV) 2018 where psoriasis took centre stage, …
UCB brings promising plaque psoriasis data to EADV 2018
September 14, 2018Medical Communications, Research and Development EADV 2018, UCB, pharma, psoriasis
UCB has joined in on the wave of new psoriasis data emerging from the European Academy of Dermatology and Venereology …
Novartis doubles down on Cosentyx’s efficacy in psoriasis with extensive real-world data
September 13, 2018Research and Development Cosentyx, Novartis, pharma, psoriasis
Novartis was yet another company to reveal new data on a psoriasis drug at the European Academy of Dermatology and …
Celgene’s Otezla produces “meaningful benefits” beyond traditional metrics in plaque psoriasis
September 13, 2018Research and Development Celgene, otezla, pharma, psoriasis
Celgene made its voice heard amongst the chorus of new psoriasis data emerging from the European Academy of Dermatology and …
Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis
September 13, 2018Research and Development Humira, Janssen, Tremfya, pharma, psoriasis
Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …
BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2
September 12, 2018Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis
Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …
FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns
June 19, 2018Manufacturing and Production, Sales and Marketing FDA, Valeant, pharma, psoriasis
Beleaguered pharma firm Valeant has come up against another bump in the road as its plaque psoriasis lotion Duobrii (halobetasol …
UCB’s Cimzia secures first-of-its-kind FDA approval in plaque psoriasis
May 29, 2018Manufacturing and Production, Sales and Marketing Cimzia, FDA, UCB, US, pharma, psoriasis
The FDA has expanded the label for UCB’s Cimzia (certolizumab pegol) in the US, approving the therapy for the treatment …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
